Claims for Patent: 9,850,313

Summary for Patent: 9,850,313

Title:	Cancer biomarkers and methods of use thereof
Abstract:	Methods and compositions for treating cancer, particularly breast cancer, are disclosed.
Inventor(s):	Band; Vimla (Omaha, NE), Band; Hamid (Omaha, NE), Mirza; Sameer (Omaha, NE)
Assignee:	Board of Regents of the University of Nebraska (Lincoln, NE)
Application Number:	14/416,502
Patent Claims:	1. A method for treating breast cancer in a subject, said method comprising: a) determining the cellular localization of alteration/deficiency in activation-3 (ADA3) in a biological sample obtained from said subject, wherein said biological sample is a breast cancer tissue sample; and b) administering hormonal therapy to said subject when ADA3 is determined to be predominantly nuclear and administering human epidermal growth factor receptor 2 (HER2) targeted therapy when ADA3 is determined to be predominantly cytoplasmic or overexpressed, thereby treating the breast cancer in said subject. 2. The method of claim 1, wherein human epidermal growth factor receptor 2 (HER2) targeted therapy is administered when ADA3 is determined to be predominantly cytoplasmic. 3. The method of claim 1, further comprising detecting at least one other breast cancer marker in said biological sample. 4. The method of claim 3, wherein said other breast cancer marker is selected from the group consisting of estrogen receptor (ER), progesterone receptor (PR), HER2, and epidermal growth factor receptor (EGFR). 5. The method of claim 4, wherein the other breast cancer marker is ER and/or PR, and wherein said subject is administered hormonal therapy when ADA3 is determined to be predominantly nuclear and the biological sample is positive for ER and/or PR. 6. The method of claim 4, wherein the other breast cancer marker is HER2 and/or EGFR, and wherein said subject is administered HER2-targeted therapy when ADA3 is determined to be predominantly cytoplasmic and the biological sample is positive for HER2 and/or EGFR. 7. The method of claim 1, wherein said hormonal therapy comprises the administration of at least one estrogen receptor modulator or aromatase inhibitor. 8. The method of claim 1, wherein said HER2-targeted therapy comprises the administration of at least one inhibitor of HER2 or antibody immunologically specific for HER2. 9. The method of claim 8, wherein said or antibody immunologically specific for HER2 is trastuzumab. 10. The method of claim 1, further comprising the administration of at least one other chemotherapeutic agent. 11. The method of claim 1, further comprising treating the subject with radiation or resecting cancerous cells from said subject. 12. A method for treating breast cancer in a subject, said method comprising: a) determining the cellular localization of alteration/deficiency in activation-3 (ADA3) in a biological sample obtained from said subject, wherein said biological sample is a breast cancer tissue sample; and b) administering hormonal therapy to said subject when ADA3 is determined to be predominantly nuclear, thereby treating the breast cancer in said subject.

Details for Patent 9,850,313

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-08-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-08-03
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2032-08-03